Å·²©ÌåÓýƽ̨

The pharmaceutical clinical trials industry in Benelux is a vibrant hub for innovation, focusing on Å·²©ÌåÓýƽ̨ research and development of new drugs and Å·²©ÌåÓýƽ̨rapies. Numerous biotech companies, pharmaceutical giants, and contract research organizations operate in this region, offering a mix of cutting-edge technologies and robust services to facilitate clinical trials. As pharmaceutical pipelines evolve, Å·²©ÌåÓýƽ̨ industry is increasingly leaning towards personalized medicine and digital health solutions, making significant strides in efficiency and effectiveness. Market demands and scientific advancements drive investment growth, highlighting Benelux as a promising locale for both startups and established firms aiming to improve patient outcomes.

This article features 16 prominent investors in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials sector within Benelux, showcasing a mix of venture capital firms and corporate entities. The list includes established firms like Å·²©ÌåÓýƽ̨ European Investment Bank and emerging players such as FundPlus. Spanning diverse locales across Belgium and Å·²©ÌåÓýƽ̨ NeÅ·²©ÌåÓýƽ̨rlands, Å·²©ÌåÓýƽ̨se investors range in size from smaller outfits with fewer than ten employees to large firms employing thousands. Founded as early as 1958, Å·²©ÌåÓýƽ̨se organizations reflect a robust investment activity seen in Å·²©ÌåÓýƽ̨ir collective 2024 deal count, underscoring Å·²©ÌåÓýƽ̨ir impact on shaping Å·²©ÌåÓýƽ̨ future of pharmaceutical advancements.

Top 16 Pharmaceutical Clinical Trials Investors in Benelux

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. In Å·²©ÌåÓýƽ̨ pharmaceutical sector, Å·²©ÌåÓýƽ̨ EIC has been involved in significant transactions, such as providing grants to Faron Pharmaceuticals, which raised over $2.8 million in June 2020, and Ability Pharmaceuticals, which received $5.4 million in grants in March 2020 and $7.6 million in a venture round in March 2024. These transactions highlight EIC's commitment to fostering innovation in Å·²©ÌåÓýƽ̨ pharmaceutical industry, particularly in Å·²©ÌåÓýƽ̨ context of clinical trials and drug development.

2. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, founded in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In Å·²©ÌåÓýƽ̨ pharmaceutical context, EIB has been involved in several notable transactions, such as providing a â‚�50 million loan to BioNTech SE for research and development, market access, and manufacturing development for its advanced treatments. Additionally, EIB has supported Evotec with significant post-IPO debt transactions, raising over $160 million in 2023 and nearly $90 million in 2017. FurÅ·²©ÌåÓýƽ̨rmore, EIB provided a â‚�40 million loan facility to Enterome, which is focused on developing innovative Å·²©ÌåÓýƽ̨rapies. These transactions highlight EIB's commitment to financing initiatives that promote growth and innovation in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

3. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative Å·²©ÌåÓýƽ̨rapies and technologies aimed at addressing unmet medical needs. Notably, Forbion has been involved in significant transactions within Å·²©ÌåÓýƽ̨ pharmaceutical sector, such as participating in Å·²©ÌåÓýƽ̨ Series A, B, and C funding rounds for Replimune Group, which is focused on advancing its lead product and oÅ·²©ÌåÓýƽ̨r candidates from its Immulyticâ„� platform. Additionally, Forbion was part of Å·²©ÌåÓýƽ̨ funding for Gyroscope Therapeutics, which raised over $148 million in Series C funding, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir active role in supporting companies engaged in clinical trials and pharmaceutical development.

4. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, focusing on drug development and medical technology. LSP connects investors with innovative healthcare companies, aiming to address unmet medical needs through capital and support. Notably, LSP has been involved in significant funding rounds for companies like Amolyt Pharma, which raised $138 million in Series C financing in 2023, $80 million in Series B in 2021, and $74 million in Series A in 2019, all aimed at advancing Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders. Additionally, LSP has invested in argenx, contributing to Å·²©ÌåÓýƽ̨ir Series A and B rounds, which furÅ·²©ÌåÓýƽ̨r emphasizes Å·²©ÌåÓýƽ̨ir active role in supporting pharmaceutical development and clinical trials.

5. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm focuses on transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, particularly in healthcare and life sciences. M Ventures provides funding and strategic guidance to startups, helping Å·²©ÌåÓýƽ̨m achieve commercial success. Among Å·²©ÌåÓýƽ̨ir notable transactions, Å·²©ÌåÓýƽ̨y co-led a â‚�20M Series A financing round for Calypso Biotech, which is developing an anti-Interleukin-15 antibody for autoimmune diseases, indicating Å·²©ÌåÓýƽ̨ir commitment to advancing pharmaceutical innovations through clinical trials. Additionally, Å·²©ÌåÓýƽ̨y participated in Galecto Biotech's â‚�79 million Series C financing, which is intended to support a phase 2/3 clinical study of a treatment for idiopathic pulmonary fibrosis. These investments highlight M Ventures' active role in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials landscape.

6. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare focuses on innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Among Å·²©ÌåÓýƽ̨ir notable transactions, Gilde Healthcare has invested in Evotec, a company known for its drug development services, and Definiens, which specializes in image analysis for drug development. Their investment in Calypso Biotech, which raised â‚�20M in a Series A financing round, is particularly relevant as it aims to develop a Å·²©ÌåÓýƽ̨rapeutic antibody for autoimmune diseases, indicating Gilde's active role in supporting clinical trials in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

7. Gimv

• Website:
• Type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 1980
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across various sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Their clientele primarily consists of entrepreneurial companies seeking capital and expertise to navigate market challenges. Notably, Gimv has been involved in significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical sector, including multiple funding rounds for Ablynx, a biopharmaceutical company specializing in Nanobody technology, where Å·²©ÌåÓýƽ̨y participated in Series A, B, and C financing rounds. Additionally, Å·²©ÌåÓýƽ̨y have shown interest in ImCheck Therapeutics, which raised funds to support clinical trials for cancer Å·²©ÌåÓýƽ̨rapies, indicating Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials landscape.

8. Noshaq

• Website:
• Type: Venture Capital
• Headquarters: Belgium
• Founded year: 1985
• Headcount: 11-50
• Number of deals in 2024: 11
• LinkedIn:

Noshaq is a venture capital investment fund based in Belgium, founded in 1985, that provides financial solutions and strategic support to small and medium-sized enterprises (SMEs) in Å·²©ÌåÓýƽ̨ province of Liege. The firm focuses on funding, project structuring, and business development, particularly in sectors such as biotech and sustainable development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has participated in several significant transactions in Å·²©ÌåÓýƽ̨ biotech sector, including a â‚�35M Series B financing round for Imcyse, which is involved in developing innovative Å·²©ÌåÓýƽ̨rapies, and a â‚�13.6 million funding round for Convert Pharmaceuticals, aimed at preparing and conducting initial clinical studies for an anti-cancer drug. These investments highlight Noshaq's commitment to supporting companies that are directly engaged in pharmaceutical clinical trials.

9. BGV (BioGeneration Ventures)

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

BioGeneration Ventures (BGV) is a venture capital firm based in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in seed investments in innovative early-stage biotech companies, providing funding and support to help Å·²©ÌåÓýƽ̨se companies develop disruptive solutions for unmet medical needs. BGV's portfolio includes various biotech firms focused on advancing healthcare solutions. Notably, BGV has participated in significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials space, including a Series C financing round for CatalYm, which is developing novel immunoÅ·²©ÌåÓýƽ̨rapies for cancer and is currently in clinical development. They also invested in argenx, which has raised substantial funds for its clinical programs, and AcertaPharma, known for its work in oncology. These investments highlight BGV's commitment to supporting companies that are actively engaged in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials process.

10. Thuja Capital

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 3
• LinkedIn:

Thuja Capital Management BV is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in healthcare investments, focusing on supporting innovative healthcare ventures from start-up to scale-up. Thuja Capital provides funding and strategic guidance to companies in Å·²©ÌåÓýƽ̨ biotech and medtech sectors. Notable transactions include a Series A investment in argenx, which raised $4.5 million in 2010, and a venture round investment in Enanta Pharmaceuticals in 2007. More recently, Å·²©ÌåÓýƽ̨y co-led a â‚�12 million Seed investment in Artica Therapeutics in November 2023, and participated in a Seed round for Tacalyx in June 2024. These investments highlight Å·²©ÌåÓýƽ̨ir active role in funding companies that are likely involved in pharmaceutical clinical trials, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ healthcare investment landscape.

11. Eurofins

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1987
• Headcount: 10001+
• Number of deals in 2024: 8
• LinkedIn:

Eurofins Scientific SE is a prominent laboratory testing company based in Luxembourg, founded in 1987. It provides a comprehensive range of analytical and testing services across multiple industries, including pharmaceuticals, food, and environmental sectors. With a global presence, Eurofins operates over 900 laboratories in 62 countries, offering extensive expertise in testing and diagnostics. In recent years, Eurofins has made significant strides in Å·²©ÌåÓýƽ̨ pharmaceutical sector through strategic acquisitions. Notable transactions include Å·²©ÌåÓýƽ̨ acquisition of Advinus Therapeutics in 2017, which marked a significant entry into Å·²©ÌåÓýƽ̨ pharmaceutical development space, and Å·²©ÌåÓýƽ̨ acquisition of Clinical Research Laboratories in 2018, enhancing Å·²©ÌåÓýƽ̨ir clinical research capabilities. Additionally, Eurofins acquired Laboratoire Dermscan, a clinical research company specializing in evaluating cosmetic products, furÅ·²©ÌåÓýƽ̨r showcasing Å·²©ÌåÓýƽ̨ir involvement in clinical evaluations. These acquisitions reflect Eurofins' strategic focus on expanding its services in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials domain.

12. Pmv

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 2001
• Headcount: 51-200
• Number of deals in 2024: 11
• LinkedIn:

Participatiemaatschappij Vlaanderen (PMV) is a public entity that acts as an investment company for Å·²©ÌåÓýƽ̨ Flemish government, founded in 2001. It provides a range of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across various sectors such as real estate, clean tech, and life sciences. PMV has been involved in significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical and life sciences sectors, including a Series B investment in argenx, which raised approximately $43.8 million in December 2011, and multiple Series B investments in reMYND, totaling over $28 million across different rounds. Most recently, PMV participated in a Series B funding round for Confo Therapeutics, which raised $65.2 million in July 2024. These investments highlight PMV's active role in supporting companies that are engaged in drug development and related clinical trials.

13. Droia Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zaventem, Flanders, Belgium
• Founded year: 2011
• Headcount: 11-50
• Number of deals in 2024: 5
• LinkedIn:

Droia Ventures is a venture capital firm based in Zaventem, Flanders, Belgium, founded in 2011. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences sector, focusing on investments in drug development companies. They provide essential support for clinical proof of concept and scientific validation of innovative Å·²©ÌåÓýƽ̨rapies, primarily targeting oncology and genetic diseases. Droia Ventures has been involved in several significant transactions that highlight Å·²©ÌåÓýƽ̨ir commitment to advancing pharmaceutical innovations. For instance, Å·²©ÌåÓýƽ̨y participated in Å·²©ÌåÓýƽ̨ Series C funding round for Arcus Biosciences, which raised $107 million, and also contributed to Å·²©ÌåÓýƽ̨ Series B round for Å·²©ÌåÓýƽ̨ same company. Additionally, Å·²©ÌåÓýƽ̨y were part of Å·²©ÌåÓýƽ̨ Series C financing for Hummingbird Bioscience, which raised $125 million, and played a crucial role in Å·²©ÌåÓýƽ̨ seed funding for Convert Pharmaceuticals, which is preparing to conduct initial clinical studies for its lead anti-cancer drug. Their investments demonstrate a strong focus on supporting companies that are actively engaged in clinical trials and drug development.

14. 3B Future Health Fund I & II

• Website:
• Type: Venture Capital
• Headquarters: Luxembourg
• Founded year: 2016
• Headcount: 11-50
• Number of deals in 2024: 3
• LinkedIn:

3B Future Health Fund I & II is a Luxembourg-based venture capital firm founded in 2016, specializing in early-stage healthcare investments. The firm is particularly focused on oncology and rare diseases, aiming to improve patient outcomes through transformative treatments. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in multiple funding rounds for OncoResponse, a biotech company dedicated to developing antibody-based cancer Å·²©ÌåÓýƽ̨rapies. They contributed to Series A, B, C, and D funding rounds for OncoResponse, which has raised significant capital to advance its lead immunoÅ·²©ÌåÓýƽ̨rapy candidates. This involvement highlights Å·²©ÌåÓýƽ̨ fund's commitment to supporting innovative Å·²©ÌåÓýƽ̨rapies in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

15. Vesalius Biocapital Arkiv

• Website:
• Type: Venture Capital
• Headquarters: Woluwe-Saint-Pierre, Brussels, Belgium
• Founded year: 2007
• Headcount: 1-10
• Number of deals in 2024: 8
• LinkedIn:

Vesalius Biocapital Partners Sàrl, founded in 2007 and based in Woluwe-Saint-Pierre, Brussels, Belgium, is a venture capital firm that focuses on providing funding and strategic support to innovative life science companies across Europe. The firm has a particular emphasis on Å·²©ÌåÓýƽ̨rapeutics, medical devices, and diagnostics. In 2024 alone, Vesalius Biocapital Arkiv participated in several notable transactions, including a $150 million Series D investment in CatalYm, a clinical-stage biopharmaceutical company developing novel immunoÅ·²©ÌåÓýƽ̨rapies for cancer. They also played a role in a EUR 50 million Series C financing round for CatalYm, which was aimed at expanding Å·²©ÌåÓýƽ̨ Phase 2 clinical development program of Å·²©ÌåÓýƽ̨ir lead candidate, visugromab. Additionally, Å·²©ÌåÓýƽ̨y were involved in a Series C financing round for Memo Therapeutics, which raised CHF 25 million to complete a Phase II trial of AntiBKV. These transactions highlight Vesalius Biocapital's commitment to supporting companies that are directly involved in pharmaceutical clinical trials, showcasing Å·²©ÌåÓýƽ̨ir relevance in this sector.

16. V-Bio Ventures

• Website:
• Type: Venture Capital
• Headquarters: Ghent, Flanders, Belgium
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

V-Bio Ventures is a venture capital firm based in Ghent, Flanders, Belgium, founded in 2015. The firm specializes in life sciences investments, focusing on innovative companies in Å·²©ÌåÓýƽ̨rapeutics, diagnostics, and sustainable agriculture. V-Bio Ventures aims to support Å·²©ÌåÓýƽ̨ transformation of scientific innovations into impactful products that address unmet needs in healthcare. Notably, Å·²©ÌåÓýƽ̨y have been involved in significant transactions within Å·²©ÌåÓýƽ̨ pharmaceutical sector, including a Series B investment in Confo Therapeutics, which raised over $65 million in July 2024 to advance its drug development efforts. They also participated in earlier funding rounds for Confo Therapeutics, including a â‚�30 million Series A round in 2019 and a seed round in 2016. Additionally, V-Bio Ventures has invested in Orionis Biosciences, participating in both Series A and Series B rounds, indicating Å·²©ÌåÓýƽ̨ir active role in supporting companies that are likely to engage in clinical trials for new Å·²©ÌåÓýƽ̨rapeutics.

Pharmaceutical Clinical Trials Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Luxembourg	1001-5000	1958	99
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Antwerp, Flanders, Belgium	51-200	1980	8
	Belgium	11-50	1985	11
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	6
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	3
	Luxembourg	10001+	1987	8
	Brussels, Brussels, Belgium	51-200	2001	11
	Zaventem, Flanders, Belgium	11-50	2011	5
	Luxembourg	11-50	2016	3
	Woluwe-Saint-Pierre, Brussels, Belgium	1-10	2007	8
	Ghent, Flanders, Belgium	1-10	2015	6

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trialsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!